BERLIN (Reuters) – Germany’s IDT Biologika plans to start a phase II trial of its experimental COVID-19 vaccine by the end of the year and hopes to be able to apply for approval in 2021, its Chief Executive said on Monday.
“If all clinical tests are successful, we could apply for an accelerated approval at the end of 2021,” said Juergen Betzing at a news conference in Dessau.
(Reporting by Thomas Seythal and Kirsti Knolle)
